Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 6/19/14  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Dan Shochat

Wrong Dr. Dan Shochat?
 
Background

Employment History

Board Memberships and Affiliations

  • Member, Scientific Advisory Board
    ImaginAb Inc
  • Founder
    Celscia Therapeutics
  • Member of the Technical Advisory Committee To the Board of Directors
    ANSTO companies

Education

  • Ph.D. , biochemistry
    Louisiana State University Medical Center
  • Bachelor of Science , biology
    Hebrew University
  • Master in Science , physiology
    Hebrew University
25 Total References
Web References
Scientific Advisory Board
www.modigenetech.com, 27 Oct 2011 [cached]
Dan Shochat, Ph.D. led the development of Bexxar®, a radioiodinated antibody for the treatment of Non-Hodgkin's Lymphoma, which was approved by the FDA in June 2003. At American Cyanamide Co., Dr. Shochat led the development, in collaboration with Celltech, of the first approved antibody-drug conjugate, Mylotarg®; Invented the technology and single-vial formulation, and then developed the FDA-approved in vivo tumor-imaging reagent CEA-Scan®. Dr. Shochat is currently Executive Vice President of Development of KaloBios, Inc. Formerly, Dr. Shochat was Director, Product R&D, Immunomedics; Director of Biotechnology Development at American Cyanamid Co.; Senior Vice President and Chief Scientific Officer Coulter Pharmaceutical, Inc.; Ph.D. in Biochemistry from L.S.U. Medical School in New Orleans, LA.
About AMD :: Intellect Neurosciences, Inc
www.intellectns.com, 8 June 2014 [cached]
IN-N01-OX2 development is being led by Dan Shochat, Ph.D., Consulting Vice President Development, an internationally recognized leader in the development of antibody products. Dr. Shochat led the development of Bexxar®, a radioiodinated antibody for the treatment of Non-Hodgkin's Lymphoma, which was approved by the FDA in June 2003. At American Cyanamide Co. and in collaboration with Celltech, Dr. Shochat led the development of the first approved antibody-drug conjugate, Mylotarg®. He also invented the technology and single-vial formulation and then developed the FDA-approved in vivo tumor-imaging reagent CEA-Scan®. With Dr. Shochat's expert assistance, Intellect has developed a detailed road-map for IN-N01-OX2 development to lead to the first clinical trials being initiated by the end of 2014.
Management Team :: Intellect Neurosciences, Inc
www.intellectns.com, 19 Sept 2012 [cached]
Dan Shochat, Ph.D. Vice President
Dan Shochat, Ph.D. has more than 28 years of experience in the biotechnology industry and is a pioneer in the antibody development arena. Prior to joining Intellect, he served as vice president of nonclinical development at KaloBios Therapeutics. Prior, he was among the first employees of Immunomedics Inc., Newark, NJ where he served as group director, product R&D. Dr. Shochat is the inventor of several technologies, including that of the approved in vivo tumor-imaging agent CEA-Scan; Mylotarg - the first approved antibody-cytotoxic drug conjugate; and the design, process and formulation for the commercial radiolabeling of the B1 antibody at a 55 Curie scale. The lead product from this work was Bexxar, a radioiodinated antibody for the treatment of Non-Hodgkin's Lymphoma that was approved by the FDA on June 2003. He is co-founder of Celscia Therapeutics Inc. - a therapeutic antibodies development company - which merged with KaloBios Therapeutics in January 2004.
From 2001 to 2007 Dr. Shochat was a member of the Technical Advisory Committee to the Board of Directors of the Australian Nuclear Science and Technology Organization. He also serves as consultant and member of scientific advisory boards of several biopharmaceutical companies and venture capital funds.
Dr. Shochat earned B.Sc. in Zoology and Physiology (1965) and M.Sc. in Physiology (1968) from the Hebrew University of Jerusalem, Israel and Ph.D. in Biochemistry and Protein Chemistry (1976) from LSU Medical Center, New Orleans, LA. He was a post-doctoral fellow in the Department of Biochemistry (1975-1978) and Sr. Research Associate at the Division of Experimental Pathology (1978-1983), the University of Kentucky Medical Center, Lexington, KY. In 1983 he participated in founding the Center for Molecular Medicine and Immunology at the University of Medicine and Dentistry of New Jersey, Newark, NJ, where he was an Associate Member until he joint Immunomedics, Inc. in 1984. From 1986-1992 Dr. Shochat served successively as visiting lecturer and adjunct professor at the Chemistry Department of Rutgers University Graduate School (Newark, NJ campus).
Scientific Advisory
imaginab.com, 1 Mar 2013 [cached]
Dan Shochat, PhD
Dr. Shochat is Vice President of Nonclinical Development at KaloBios Pharmaceuticals Inc., a biopharmaceutical company specializing in the development of therapeutic antibodies. Dr. Shochat has over 24 years of experience in the biotechnology industry and is a pioneer in the antibody development arena. He has led groups involved with the development of several antibody based therapeutic and imaging agents including the in vivo tumor-imaging agent CEA-Scan, the first approved antibody-cytotoxic drug conjugate Mylotarg, and the radioiodinated antibody Bexxar for the treatment of Non-Hodgkin's Lymphoma. Dr. Shochat is a past member of the Technical Advisory Committee for the Australian Nuclear Science and Technology Organization and has held faculty appointments at the University of Medicine and Dentistry of New Jersey and Rutgers University Graduate School. Dr. Shochat also acts as a consultant and a member of the scientific advisory boards of several biopharmaceutical companies and venture capital funds.
Dr. Dan Shochat, Ph.D joins ...
www.imaginab.com, 1 April 2013 [cached]
Dr. Dan Shochat, Ph.D joins the ImaginAb Scientific Advisory Board
Posted Sat, 06/05/2010 - 07:06
Dr. Dan Shochat, Ph.D joins the ImaginAb Scientific Advisory Board and brings with him enormous experience in the antibody radioconjugate world including his work with the development of Bexxar and Mylotarg.
Read more about Dr. Dan Shochat, Ph.D joins the ImaginAb Scientific Advisory Board
Other People with the name "Shochat":
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304